sj-docx-1-opp-10.1177_10781552231189192 - Supplemental material for Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia

sj-docx-1-tah-10.1177_20406207221146031 – Supplemental material for Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study

Wenrui Yang (4616332)
Xu Liu (276996)
Xin Zhao (71840)
Li Zhang (8200)
Guangxin Peng (12323660)
Lei Ye (104076)
Kang Zhou (122652)
Yuan Li (67017)
Jianping Li (300447)
Huihui Fan (182099)
Yang Yang (45629)
Youzhen Xiong (14369676)
Liping Jing (11223939)
Fengkui Zhang (8539947)

January 2023

Supplemental material, sj-docx-1-tah-10.1177_20406207221146031 for Antihuman T lymphocyte porcine im...

sj-docx-1-opp-10.1177_10781552221126174 - Supplemental material for Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors

Yanyu Wu (6634754)
Kaili Ren (3845098)
Yin Wan (4164121)
Huamao M Lin (12614506)

September 2022

Supplemental material, sj-docx-1-opp-10.1177_10781552221126174 for Economic burden in patients with ...

sj-docx-3-tah-10.1177_20406207231155028 – Supplemental material for Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis

Linchun Xu (14723844)
Shaoze Lin (12548500)
Xueyang Xing (14723847)
Yongzhong Su (551868)

March 2023

Supplemental material, sj-docx-3-tah-10.1177_20406207231155028 for Efficacy and safety of venetoclax...

sj-docx-1-opp-10.1177_10781552231203723 - Supplemental material for Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration

Xiangjian Wang (1530259)
Tao Fu (477112)
Weilian Sun (10954867)

October 2023

Supplemental material, sj-docx-1-opp-10.1177_10781552231203723 for Camrelizumab-induced oral licheno...

sj-docx-1-onc-10.1177_11795549231218082 – Supplemental material for A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma

Yoon Jung Jang (1921081)
Sang Moo Lim (1601515)
Inki Lee (8222859)
Byung Hyun Byun (2620918)
Ilhan Lim (2620915)
Byung Il Kim (1601527)
Chang Woon Choi (2620924)
Seung-Sook Lee (3720403)
Sung Hyun Yang (2156953)
Im Il Na (15088017)
Hyo-Rak Lee (17620714)
Dong-Yeop Shin (3269553)
Hye Jin Kang (4103293)

December 2023

Supplemental material, sj-docx-1-onc-10.1177_11795549231218082 for A Phase II Study of 131I-rituxima...

sj-docx-1-opp-10.1177_10781552221150936 - Supplemental material for Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis

Won Jin Jeon (14440812)
Jasmine Nguyen (2604274)
Dani Ran Castillo (14440815)
Kiwon Park (6492266)
Joel Brothers (14440818)
Anthony Nguyen (312850)
Hamid Mirshahidi (14440821)

January 2023

Supplemental material, sj-docx-1-opp-10.1177_10781552221150936 for Recurrent and atypical immune che...

sj-docx-1-tam-10.1177_17588359221148541 – Supplemental material for Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma

Jaekyung Cheon (6735305)
Hyeyeong Kim (12415075)
Han Sang Kim (5474396)
Chang Gon Kim (11928258)
Ilhwan Kim (5235122)
Beodeul Kang (3585176)
Chan Kim (467480)
Sanghoon Jung (13107311)
Yeonjung Ha (14426256)
Hong Jae Chon (8907980)

January 2023

Supplemental material, sj-docx-1-tam-10.1177_17588359221148541 for Atezolizumab plus bevacizumab in ...

sj-docx-1-opp-10.1177_10781552231210788 - Supplemental material for Patterns of prescription opioid use and opioid-related harms among adult patients with hematologic malignancies

Nadia A Nabulsi (13029586)
Lisa K Sharp (17372588)
Karen I Sweiss (17372591)
Pritesh R Patel (17372594)
Gregory S Calip (13029601)
Todd A Lee (7943360)

November 2023

Supplemental material, sj-docx-1-opp-10.1177_10781552231210788 for Patterns of prescription opioid u...

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Dreger, Peter
Michallet, Mauricette
Bosman, Paul
Dietrich, Sascha
Sobh, Mohamad
Boumendil, Ariane
Schaap, M.
Montoto, Silvia
Schetelig, Johannes

January 2019

Contains fulltext : 201051.pdf (publisher's version ) (Closed access

sj-docx-1-opp-10.1177_10781552231203703 - Supplemental material for Cabozantinib-induced heart failure

Serhat Sekmek (17130155)
Dogan Bayram (17130158)
Gokhan Ucar (17007899)
Burak Civelek (17130161)
Fahriye Tugba Kos (17130164)
Dogan Uncu (17130167)

October 2023

Supplemental material, sj-docx-1-opp-10.1177_10781552231203703 for Cabozantinib-induced heart failur...

sj-docx-1-tah-10.1177_20406207231154713 – Supplemental material for Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–matched cohort analysis

Jae-Ho Yoon (3690328)
Daehun Kwag (11881456)
Jong-Hyuk Lee (1920298)
Gi June Min (11477204)
Sung-Soo Park (165114)
Silvia Park (8946710)
Sung-Eun Lee (567452)
Byung-Sik Cho (3690340)
Ki-Seong Eom (3690331)
Yoo-Jin Kim (1814863)
Hee-Je Kim (3690343)
Chang-Ki Min (3407861)
Seok-Goo Cho (424174)
Jong Wook Lee (513589)
Seok Lee (561348)

March 2023

Supplemental material, sj-docx-1-tah-10.1177_20406207231154713 for Superior survival outcome of blin...

sj-docx-1-onc-10.1177_11795549231216427 – Supplemental material for BCL11B Mutations Are Associated with Higher CD8+ T-Cell Percentage and Favorable Clinical Outcomes in Patients with T-Cell Acute Lymphoblastic Leukemia

Cunte Chen (10143638)
Yuping Zhang (136067)
Xiangbo Zeng (7374461)
Chengwu Zeng (3505088)
Grzegorz K Przybylski (17563816)
Yangqiu Li (1495978)

December 2023

Supplemental material, sj-docx-1-onc-10.1177_11795549231216427 for BCL11B Mutations Are Associated w...

sj-docx-1-opp-10.1177_10781552221137709 - Supplemental material for Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant

Navya Gupta (14069003)
Latha Sneha Magatha (14069006)
Dhaarani Jayaraman (14069009)
Julius Xavier Scott (11895195)
Sharon Benita Antony (14069012)
Teena Koshy (665585)

November 2022

Supplemental material, sj-docx-1-opp-10.1177_10781552221137709 for Mercaptopurine induced myelosuppr...

sj-docx-1-tah-10.1177_20406207221127532 – Supplemental material for Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation

Meng Zhou (105903)
Jiaqian Qi (10008962)
Chengyuan Gu (441600)
Hong Wang (13528)
Ziyan Zhang (800393)
Depei Wu (239078)
Yue Han (560788)

September 2022

Supplemental material, sj-docx-1-tah-10.1177_20406207221127532 for Avatrombopag for the treatment of...

sj-docx-1-tah-10.1177_20406207231155028 – Supplemental material for Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis

Linchun Xu (14723844)
Shaoze Lin (12548500)
Xueyang Xing (14723847)
Yongzhong Su (551868)

March 2023

Supplemental material, sj-docx-1-tah-10.1177_20406207231155028 for Efficacy and safety of venetoclax...

sj-docx-1-tah-10.1177_20406207221146031 – Supplemental material for Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study

Wenrui Yang (4616332)
Xu Liu (276996)
Xin Zhao (71840)
Li Zhang (8200)
Guangxin Peng (12323660)
Lei Ye (104076)
Kang Zhou (122652)
Yuan Li (67017)
Jianping Li (300447)
Huihui Fan (182099)
Yang Yang (45629)
Youzhen Xiong (14369676)
Liping Jing (11223939)
Fengkui Zhang (8539947)

January 2023

Supplemental material, sj-docx-1-tah-10.1177_20406207221146031 for Antihuman T lymphocyte porcine im...

sj-docx-1-opp-10.1177_10781552221126174 - Supplemental material for Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors

Yanyu Wu (6634754)
Kaili Ren (3845098)
Yin Wan (4164121)
Huamao M Lin (12614506)

September 2022

Supplemental material, sj-docx-1-opp-10.1177_10781552221126174 for Economic burden in patients with ...

sj-docx-3-tah-10.1177_20406207231155028 – Supplemental material for Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis

Linchun Xu (14723844)
Shaoze Lin (12548500)
Xueyang Xing (14723847)
Yongzhong Su (551868)

March 2023

Supplemental material, sj-docx-3-tah-10.1177_20406207231155028 for Efficacy and safety of venetoclax...

sj-docx-1-opp-10.1177_10781552231203723 - Supplemental material for Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration

Xiangjian Wang (1530259)
Tao Fu (477112)
Weilian Sun (10954867)

October 2023

Supplemental material, sj-docx-1-opp-10.1177_10781552231203723 for Camrelizumab-induced oral licheno...

sj-docx-1-onc-10.1177_11795549231218082 – Supplemental material for A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma

Yoon Jung Jang (1921081)
Sang Moo Lim (1601515)
Inki Lee (8222859)
Byung Hyun Byun (2620918)
Ilhan Lim (2620915)
Byung Il Kim (1601527)
Chang Woon Choi (2620924)
Seung-Sook Lee (3720403)
Sung Hyun Yang (2156953)
Im Il Na (15088017)
Hyo-Rak Lee (17620714)
Dong-Yeop Shin (3269553)
Hye Jin Kang (4103293)

December 2023

Supplemental material, sj-docx-1-onc-10.1177_11795549231218082 for A Phase II Study of 131I-rituxima...

sj-docx-1-opp-10.1177_10781552221150936 - Supplemental material for Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis

Won Jin Jeon (14440812)
Jasmine Nguyen (2604274)
Dani Ran Castillo (14440815)
Kiwon Park (6492266)
Joel Brothers (14440818)
Anthony Nguyen (312850)
Hamid Mirshahidi (14440821)

January 2023

Supplemental material, sj-docx-1-opp-10.1177_10781552221150936 for Recurrent and atypical immune che...

sj-docx-1-tam-10.1177_17588359221148541 – Supplemental material for Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma

Jaekyung Cheon (6735305)
Hyeyeong Kim (12415075)
Han Sang Kim (5474396)
Chang Gon Kim (11928258)
Ilhwan Kim (5235122)
Beodeul Kang (3585176)
Chan Kim (467480)
Sanghoon Jung (13107311)
Yeonjung Ha (14426256)
Hong Jae Chon (8907980)

January 2023

Supplemental material, sj-docx-1-tam-10.1177_17588359221148541 for Atezolizumab plus bevacizumab in ...

sj-docx-1-opp-10.1177_10781552231210788 - Supplemental material for Patterns of prescription opioid use and opioid-related harms among adult patients with hematologic malignancies

Nadia A Nabulsi (13029586)
Lisa K Sharp (17372588)
Karen I Sweiss (17372591)
Pritesh R Patel (17372594)
Gregory S Calip (13029601)
Todd A Lee (7943360)

November 2023

Supplemental material, sj-docx-1-opp-10.1177_10781552231210788 for Patterns of prescription opioid u...

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Dreger, Peter
Michallet, Mauricette
Bosman, Paul
Dietrich, Sascha
Sobh, Mohamad
Boumendil, Ariane
Schaap, M.
Montoto, Silvia
Schetelig, Johannes

January 2019

Contains fulltext : 201051.pdf (publisher's version ) (Closed access

sj-docx-1-opp-10.1177_10781552231203703 - Supplemental material for Cabozantinib-induced heart failure

Serhat Sekmek (17130155)
Dogan Bayram (17130158)
Gokhan Ucar (17007899)
Burak Civelek (17130161)
Fahriye Tugba Kos (17130164)
Dogan Uncu (17130167)

October 2023

Supplemental material, sj-docx-1-opp-10.1177_10781552231203703 for Cabozantinib-induced heart failur...

sj-docx-1-tah-10.1177_20406207231154713 – Supplemental material for Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–matched cohort analysis

Jae-Ho Yoon (3690328)
Daehun Kwag (11881456)
Jong-Hyuk Lee (1920298)
Gi June Min (11477204)
Sung-Soo Park (165114)
Silvia Park (8946710)
Sung-Eun Lee (567452)
Byung-Sik Cho (3690340)
Ki-Seong Eom (3690331)
Yoo-Jin Kim (1814863)
Hee-Je Kim (3690343)
Chang-Ki Min (3407861)
Seok-Goo Cho (424174)
Jong Wook Lee (513589)
Seok Lee (561348)

March 2023

Supplemental material, sj-docx-1-tah-10.1177_20406207231154713 for Superior survival outcome of blin...

sj-docx-1-onc-10.1177_11795549231216427 – Supplemental material for BCL11B Mutations Are Associated with Higher CD8+ T-Cell Percentage and Favorable Clinical Outcomes in Patients with T-Cell Acute Lymphoblastic Leukemia

Cunte Chen (10143638)
Yuping Zhang (136067)
Xiangbo Zeng (7374461)
Chengwu Zeng (3505088)
Grzegorz K Przybylski (17563816)
Yangqiu Li (1495978)

December 2023

Supplemental material, sj-docx-1-onc-10.1177_11795549231216427 for BCL11B Mutations Are Associated w...

sj-docx-1-opp-10.1177_10781552221137709 - Supplemental material for Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant

Navya Gupta (14069003)
Latha Sneha Magatha (14069006)
Dhaarani Jayaraman (14069009)
Julius Xavier Scott (11895195)
Sharon Benita Antony (14069012)
Teena Koshy (665585)

November 2022

Supplemental material, sj-docx-1-opp-10.1177_10781552221137709 for Mercaptopurine induced myelosuppr...

sj-docx-1-tah-10.1177_20406207221127532 – Supplemental material for Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation

Meng Zhou (105903)
Jiaqian Qi (10008962)
Chengyuan Gu (441600)
Hong Wang (13528)
Ziyan Zhang (800393)
Depei Wu (239078)
Yue Han (560788)

September 2022

Supplemental material, sj-docx-1-tah-10.1177_20406207221127532 for Avatrombopag for the treatment of...

sj-docx-1-tah-10.1177_20406207231155028 – Supplemental material for Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis

Linchun Xu (14723844)
Shaoze Lin (12548500)
Xueyang Xing (14723847)
Yongzhong Su (551868)

March 2023

Supplemental material, sj-docx-1-tah-10.1177_20406207231155028 for Efficacy and safety of venetoclax...

sj-docx-1-tah-10.1177_20406207221146031 – Supplemental material for Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study

Wenrui Yang (4616332)
Xu Liu (276996)
Xin Zhao (71840)
Li Zhang (8200)
Guangxin Peng (12323660)
Lei Ye (104076)
Kang Zhou (122652)
Yuan Li (67017)
Jianping Li (300447)
Huihui Fan (182099)
Yang Yang (45629)
Youzhen Xiong (14369676)
Liping Jing (11223939)
Fengkui Zhang (8539947)

January 2023

Supplemental material, sj-docx-1-tah-10.1177_20406207221146031 for Antihuman T lymphocyte porcine im...

sj-docx-1-opp-10.1177_10781552221126174 - Supplemental material for Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors

Yanyu Wu (6634754)
Kaili Ren (3845098)
Yin Wan (4164121)
Huamao M Lin (12614506)

September 2022

Supplemental material, sj-docx-1-opp-10.1177_10781552221126174 for Economic burden in patients with ...

sj-docx-3-tah-10.1177_20406207231155028 – Supplemental material for Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis

Linchun Xu (14723844)
Shaoze Lin (12548500)
Xueyang Xing (14723847)
Yongzhong Su (551868)

March 2023

Supplemental material, sj-docx-3-tah-10.1177_20406207231155028 for Efficacy and safety of venetoclax...

sj-docx-1-opp-10.1177_10781552231189192 - Supplemental material for Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia

Abstract

Extracted data

sj-docx-1-opp-10.1177_10781552231189192 - Supplemental material for Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia

Abstract

Extracted data

Related items

Related items